288 related articles for article (PubMed ID: 32101387)
21. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
22. Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration.
Rejdak R; Junemann A; Grieb P; Thaler S; Schuettauf F; Chorągiewicz T; Zarnowski T; Turski WA; Zrenner E
Pharmacol Rep; 2011; 63(6):1324-34. PubMed ID: 22358081
[TBL] [Abstract][Full Text] [Related]
23. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
24. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
25. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats.
Koshy Cherian A; Gritton H; Johnson DE; Young D; Kozak R; Sarter M
Neuropharmacology; 2014 Jul; 82():41-8. PubMed ID: 24647121
[TBL] [Abstract][Full Text] [Related]
26. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
27. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
28. Fragment Screening of Human Kynurenine Aminotransferase-II.
Jayawickrama GS; Nematollahi A; Sun G; Church WB
SLAS Discov; 2018 Jul; 23(6):511-519. PubMed ID: 29537924
[TBL] [Abstract][Full Text] [Related]
29. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
[TBL] [Abstract][Full Text] [Related]
30. Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.
Bortz DM; Wu HQ; Schwarcz R; Bruno JP
Neuropharmacology; 2017 Jul; 121():69-78. PubMed ID: 28419874
[TBL] [Abstract][Full Text] [Related]
31. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry.
Guidetti P; Hoffman GE; Melendez-Ferro M; Albuquerque EX; Schwarcz R
Glia; 2007 Jan; 55(1):78-92. PubMed ID: 17024659
[TBL] [Abstract][Full Text] [Related]
32. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
[TBL] [Abstract][Full Text] [Related]
33. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
[TBL] [Abstract][Full Text] [Related]
34. Structural and mechanistic insights into the kynurenine aminotransferase-mediated excretion of kynurenic acid.
Okada K; Angkawidjaja C; Koga Y; Kanaya S
J Struct Biol; 2014 Mar; 185(3):257-66. PubMed ID: 24473062
[TBL] [Abstract][Full Text] [Related]
35. Sleep disturbance and kynurenine metabolism in depression.
Cho HJ; Savitz J; Dantzer R; Teague TK; Drevets WC; Irwin MR
J Psychosom Res; 2017 Aug; 99():1-7. PubMed ID: 28712413
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis.
Guillemin GJ; Smith DG; Kerr SJ; Smythe GA; Kapoor V; Armati PJ; Brew BJ
Redox Rep; 2000; 5(2-3):108-11. PubMed ID: 10939285
[TBL] [Abstract][Full Text] [Related]
37. Peripheral kynurenine metabolism in focal dystonia.
Hartai Z; Klivenyi P; Janaky T; Penke B; Dux L; Vecsei L
Med Chem; 2007 May; 3(3):285-8. PubMed ID: 17504201
[TBL] [Abstract][Full Text] [Related]
38. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.
Hartai Z; Klivenyi P; Janaky T; Penke B; Dux L; Vecsei L
J Neurol Sci; 2005 Dec; 239(1):31-5. PubMed ID: 16099471
[TBL] [Abstract][Full Text] [Related]
39. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
40. Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations.
Okuno E; Schmidt W; Parks DA; Nakamura M; Schwarcz R
J Neurochem; 1991 Aug; 57(2):533-40. PubMed ID: 2072101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
